Pharmacological strategies for neuroprotection in traumatic brain injury.
Traumatic brain injury affects over a million Americans annually, but pharmacological therapy remains limited. Current standards of care in acute, subacute and chronic phases of injury are primarily supportive. This review discusses pharmacological strategies and future directions in patient treatment emphasizing pleiotropic agents targeting inflammation, oxidative damage, and glutamate excitotoxicity.
Department of Neurosurgery, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, New York 13210, USA.
J S
JS
Jennings
A M
AM
Gerber
M L
ML
Vallano
D001930:Brain Injuries / Q000175:diagnosis / Q000188:drug therapy*; D002186:Cannabinoids / Q000819:agonists; D004660:Encephalitis / Q000188:drug therapy; D006801:Humans; D009104:Multiple Trauma / Q000175:diagnosis; D018696:Neuroprotective Agents / Q000737:chemistry* / Q000627:therapeutic use*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors
D002186:Cannabinoids; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate